These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 33646820

  • 1. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F.
    J Clin Oncol; 2021 Apr 10; 39(11):1253-1263. PubMed ID: 33646820
    [Abstract] [Full Text] [Related]

  • 2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC, trial investigators.
    Lancet Oncol; 2020 Feb 10; 21(2):261-270. PubMed ID: 31838015
    [Abstract] [Full Text] [Related]

  • 3. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
    Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong HHF, Chee CE, Garrido P, Dong X, Fan Y, Lu S, Schwemmers S, Bordogna W, Zeuner H, Osborne S, John T.
    Lung Cancer; 2024 Feb 10; 188():107442. PubMed ID: 38171156
    [Abstract] [Full Text] [Related]

  • 4. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb 10; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 5. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C.
    Clin Cancer Res; 2022 Apr 01; 28(7):1302-1312. PubMed ID: 35144967
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
    Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, Krebs MG, Liu SV, John T, Otterson GA, Tan DSW, Patil T, Dziadziuszko R, Massarelli E, Seto T, Doebele RC, Pitcher B, Kurtsikidze N, Heinzmann S, Siena S.
    JTO Clin Res Rep; 2022 Jun 01; 3(6):100332. PubMed ID: 35663414
    [Abstract] [Full Text] [Related]

  • 7. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE.
    Drugs; 2021 Apr 01; 81(6):697-708. PubMed ID: 33871816
    [Abstract] [Full Text] [Related]

  • 8. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, Pignatti F.
    ESMO Open; 2021 Apr 01; 6(2):100087. PubMed ID: 33735800
    [Abstract] [Full Text] [Related]

  • 9. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E.
    Neuro Oncol; 2022 Oct 03; 24(10):1776-1789. PubMed ID: 35395680
    [Abstract] [Full Text] [Related]

  • 10. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
    Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G.
    ESMO Open; 2021 Jun 03; 6(3):100113. PubMed ID: 33930659
    [Abstract] [Full Text] [Related]

  • 11. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
    Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R.
    Nat Med; 2024 Jul 03; 30(7):1923-1932. PubMed ID: 38898120
    [Abstract] [Full Text] [Related]

  • 12. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
    Araujo JM, Gomez AC, Pinto JA, Rolfo C, Raez LE.
    Hematol Oncol Stem Cell Ther; 2021 Sep 03; 14(3):192-198. PubMed ID: 33290717
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    Fan Y, Drilon A, Chiu CH, Loong HHF, Siena S, Krzakowski M, Dziadziuszko R, Zeuner H, Xue C, Krebs MG.
    Clin Lung Cancer; 2024 Mar 03; 25(2):e81-e86.e4. PubMed ID: 38245456
    [No Abstract] [Full Text] [Related]

  • 15. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S.
    Expert Rev Anticancer Ther; 2020 May 03; 20(5):333-341. PubMed ID: 32223357
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.
    Cancer Discov; 2017 Apr 03; 7(4):400-409. PubMed ID: 28183697
    [Abstract] [Full Text] [Related]

  • 18. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI.
    Ann Oncol; 2019 Jul 01; 30(7):1121-1126. PubMed ID: 30980071
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.